Allergen reducing agent, allergen reducing coating material and masterbatch for synthetic resin molding

Abstract

To provide an allergen reducing agent which effectively reduces reaction of allergen with a specific antibody, can reduce or prevent occurrence of allergic symptoms, and exhibits excellent allergen reducing effects.SOLUTION: An allergen reducing agent has an allergen reducing compound which has at least one H type acidic functional group selected from the group consisting of a carboxy group, a sulfo group and a phosphonic acid group, where the H type acidic functional group is bonded to a cyclic skeleton through 0 to 2 carbon atoms.SELECTED DRAWING: None

Description

[Technical field]

[0001] The present invention relates to an allergen reducing agent, an allergen reducing paint, and a masterbatch for synthetic resin molding. [Background technology]

[0002] In recent years, many allergic diseases such as atopic dermatitis, bronchial asthma, and allergic rhinitis have become a problem. The main cause of these allergic diseases is the increase in allergens in living spaces, including mites that live in homes, especially allergens such as house dust mites (Der1, Der2) that are abundant in indoor dust, and cedar pollen allergens (Cry j1, Cry j2) that float in large quantities in the air mainly in spring.

[0003] The allergens for house dust mites are not the mites themselves, but rather the corpses and feces of house dust mites, so even if the mites are eradicated, it will not fundamentally solve allergic diseases.

[0004] In addition, the cedar pollen allergens Cry j1 and Cry j2 are glycoproteins with molecular weights of approximately 40 kDa and approximately 37 kDa, respectively. When these cedar pollen allergens come into contact with the nasal mucosa, they are recognized as foreign bodies and cause an inflammatory reaction.

[0005] Therefore, there is a need for technologies to either remove allergens from living spaces or to inactivate them by denaturing them.

[0006] Patent Document 1 discloses a cellulosic fiber having an allergen treating ability, characterized in that it carries an allergen treating agent containing, as an active ingredient, a nitrogen-containing compound having a specific chemical structural formula or a solvate thereof. [Prior art documents] [Patent documents]

[0007] [Patent Document 1] JP 2007-31889 A Summary of the Invention [Problem to be solved by the invention]

[0008] However, the allergen treating ability (allergen reducing effect) of the allergen treating agent disclosed in Patent Document 1 is insufficient, and an allergen reducing agent that exerts an excellent allergen reducing effect has been desired.

[0009] The present invention provides an allergen-reducing agent that exhibits excellent allergen-reducing effects, as well as an allergen-reduced paint and a synthetic resin molding masterbatch that use this allergen-reducing agent. [Means for solving the problem]

[0010] The allergen reducing agent of the present invention is characterized in that it comprises as an active ingredient an allergen reducing compound having at least one H-type acidic functional group selected from the group consisting of a carboxy group, a sulfo group and a phosphonic acid group, and in which the H-type acidic functional group is bonded to a cyclic skeleton via 0 to 2 carbon atoms.

[0011] The allergen-reducing paint of the present invention is characterized by comprising the above-mentioned allergen-reducing agent, a synthetic resin, and a solvent.

[0012] The synthetic resin molding masterbatch of the present invention is characterized by containing the above-mentioned allergen reducing agent and a synthetic resin. Effect of the Invention

[0013] The allergen-reducing agent of the present invention exhibits an excellent allergen-reducing effect since it contains as an active ingredient an allergen-reducing compound having at least one H-type acidic functional group selected from the group consisting of a carboxy group, a sulfo group and a phosphonic acid group, and in which the H-type acidic functional group is bonded to a cyclic skeleton via 0 to 2 carbon atoms. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0014] [Allergen-reducing compounds] The allergen-reducing agent of the present invention contains, as an active ingredient, an allergen-reducing compound having at least one H-type acidic functional group selected from the group consisting of a carboxy group, a sulfo group, and a phosphonic acid group, and the H-type acidic functional group is bonded to a cyclic skeleton via 0 to 2 carbon atoms. The allergen-reducing compound may be used alone or in combination of two or more kinds.

[0015] The content of the allergen-reducing compound in the allergen-reducing agent is preferably 50% by mass or more, more preferably 60% by mass or more, more preferably 70% by mass or more, more preferably 80% by mass or more, more preferably 90% by mass or more, more preferably 95% by mass or more, more preferably 99% by mass or more, and more preferably 100% by mass.

[0016] The allergen-reducing agent exhibits excellent allergen-reducing effects by containing the allergen-reducing compound.

[0017] Here, the allergen reducing agent refers to one that has an allergen reducing effect. The allergen reducing effect can be determined by measuring the allergen reducing rate of cedar pollen allergen (Cryj1) or mite allergen (Derf1) as described below, and if the allergen reducing rate is 60% or more for at least either allergen, it can be determined that the allergen reducing effect is present.

[0018] The cedar pollen allergen (Cryj1) may be, for example, a product commercially available from ITEA under the product name "Cedar Pollen Extract, Code 10103." The mite allergen (Derf1) may be, for example, a product commercially available from ITEA under the product name "Mite Allergen Extract, Code 10102."

[0019] The freeze-dried powder of the allergen is dissolved in purified water to prepare an allergen aqueous solution containing 10 μg / mL of the allergen. Then, phosphate-buffered saline (pH 7.4, hereafter referred to as "PBS-T") containing 0.05 w / v% polysorbate 20 is added to the allergen aqueous solution and mixed uniformly to prepare an allergen solution containing 15 ng / mL of the allergen.

[0020] 0.4 g of the allergen denaturing agent is placed in a zippered plastic bag, 1 mL of the above allergen solution is dropped into it, the bag is sealed and left to stand at 25°C for 2 hours to prepare a test solution.

[0021] Next, the amount W1 (ng / mL) of the allergen present in the test liquid is measured using an ELISA measurement kit.

[0022] The cedar pollen allergen measurement kit may be, for example, a commercially available measurement kit from ITEA under the product name "Cedar Pollen Allergen (Cryj1) ELISA Kit, code 10204." The mite allergen measurement kit may be, for example, a commercially available measurement kit from ITEA under the product name "Mite Allergen (Derf1) ELISA Kit, code 10205."

[0023] The amount of allergen present in the test solution, W0 (ng / mL), is measured in the same manner as above, except that no allergen denaturing agent is placed in the zippered plastic bag. The allergen denaturation rate (%) is calculated according to the following formula: Allergen reduction rate (%) = 100-(W1 / W0) x 100

[0024] The allergen reduction rate of the allergen reducing agent is preferably 70% or more, more preferably 80% or more, more preferably 85% or more, more preferably 90% or more, and even more preferably 95% or more.

[0025] The number of H-type acidic functional groups in the allergen-reducing compound is preferably 1 to 5, more preferably 2 to 5, since the allergen-reducing effect of the allergen-reducing agent is improved. When the allergen-reducing compound has a plurality of H-type acidic functional groups, the H-type acidic functional groups may be only the same type of H-type acidic functional groups, or may contain different types of H-type acidic functional groups. Since the proton releasing ability of the H-type acidic functional groups in the allergen-reducing compound can be fully exerted, and the allergen-reducing effect of the allergen-reducing agent can be improved, it is preferable that the H-type acidic functional groups are only the same type of H-type acidic functional groups.

[0026] The H-type acidic functional group refers to a functional group capable of releasing hydrogen ions (protons) in an aqueous solution. The allergen-reducing compound has at least one acidic functional group selected from the group consisting of a carboxy group (-COOH), a sulfo group (sulfonic acid group) (-SO3H) and a phosphonic acid group [-P(=O)(OH)2]. The allergen-reducing compound preferably has a carboxy group (-COOH) and / or a sulfo group (-SO3H) as the H-type acidic functional group, and more preferably has a carboxy group (-COOH), since this improves the allergen-reducing effect of the allergen reducing agent.

[0027] In the allergen-reducing compound, the H-type acidic functional group is bonded to the cyclic skeleton via 0 to 2 carbon atoms. The H-type acidic functional group is bonded to the cyclic skeleton via 1 or 2 carbon atoms, or directly. The H-type acidic functional group is preferably bonded to the cyclic skeleton via one carbon atom [preferably a methylene group (-CH2-)] or directly by a covalent bond (direct bond). Although not clearly understood, the allergen-reducing compound is considered to have an excellent allergen-reducing effect because the H-type acidic functional group and the cyclic skeleton are bonded to each other via 0 to 2 carbon atoms, so that the H-type acidic functional group and the cyclic skeleton can be efficiently adsorbed to allergens. Since the allergen-reducing effect of the allergen-reducing agent is improved, the carbon-carbon bond bonding the H-type acidic functional group and the cyclic skeleton is preferably a single bond.

[0028] The term "an H-type acidic functional group is bonded to a cyclic skeleton via 0 to 2 carbon atoms" means that an H-type acidic functional group is bonded to an atom (preferably a carbon atom) constituting the cyclic skeleton via 0 to 2 carbon atoms. For example, when the cyclic skeleton is a benzene ring or a cyclohexane ring, the atoms constituting the cyclic skeleton refer to the 6 carbon atoms constituting the benzene ring or the cyclohexane ring. When a substituent (e.g., an alkyl group) is bonded to the benzene ring or the cyclohexane ring, the carbon atom constituting the substituent is not included.

[0029] The cyclic skeleton may be either an aromatic skeleton or an alicyclic skeleton. The cyclic skeleton preferably does not contain heteroatoms such as nitrogen atoms and sulfur atoms, and more preferably is composed of only carbon atoms and hydrogen atoms. The cyclic skeleton may be a skeleton in which an aromatic skeleton and an alicyclic skeleton are condensed.

[0030] The aromatic ring skeleton may be a monocyclic aromatic ring skeleton or a skeleton in which monocyclic aromatic rings are combined and condensed (condensed aromatic ring), but a monocyclic aromatic ring skeleton is preferred. The aromatic ring preferably does not contain a heteroatom. The aromatic ring skeleton is preferably a 4- to 10-membered ring, more preferably a 5- to 8-membered ring, and more preferably a 6-membered ring.

[0031] The aromatic ring is not particularly limited, and examples thereof include a benzene ring, a naphthalene ring, an anthracene ring, a biphenyl, and a phenoxyphenyl, among which a benzene ring and a naphthalene ring are preferred, and a benzene ring is more preferred. The aromatic ring skeleton is formed by abstracting one or more hydrogen atoms from a monocyclic aromatic ring or a condensed aromatic ring, and is bonded to other atoms by covalent bonds.

[0032] The alicyclic skeleton refers to a cyclic skeleton having a structure in which carbon atoms are bonded in a ring and having no aromaticity. The alicyclic skeleton may be monocyclic or may be a skeleton in which monocyclic skeletons are combined and condensed, but a monocyclic alicyclic skeleton is preferred. The number of carbon atoms constituting the alicyclic skeleton is preferably a 4-10 membered ring, more preferably a 5-8 membered ring, and more preferably a 6 membered ring. The alicyclic skeleton may contain an unsaturated bond (e.g., an unsaturated ethylenic double bond, etc.). The number of unsaturated bonds in the alicyclic skeleton is preferably 1-3, more preferably 1 or 2, and more preferably 1. The alicyclic skeleton preferably does not contain a heteroatom, and more preferably is composed of only carbon atoms and hydrogen atoms.

[0033] The alicyclic skeleton is not particularly limited, and examples thereof include a cycloalkane skeleton (e.g., a cyclopropane ring, a cyclobutane ring, a cyclopentane ring, a cyclohexane ring, a cycloheptane ring, a cyclooctane ring, etc.), a cycloalkene skeleton (e.g., a cyclopropene ring, a cyclobutene ring, a cyclopentene ring, a cyclohexene ring, a cycloheptene ring, a cyclooctene ring, etc.), a bicyclo skeleton (e.g., a decalin ring, a norbornane ring, a norbornene ring, an adamantane ring, etc.), etc., and a cycloalkane skeleton and a cycloalkene skeleton are preferred, a cycloalkene skeleton is more preferred, and a cyclohexene skeleton is more preferred. The alicyclic skeleton is a skeleton in which one or more hydrogen atoms of the alicyclic skeleton are removed and bonded to other atoms by a covalent bond.

[0034] As the allergen-reducing compound, compounds having the structures shown in formulas (1) to (7) and (12) are preferred.

[0035] [ka]

[0036] The pH of a 0.5% by mass aqueous solution of the allergen-reducing compound at 25°C is preferably 4.5 or less, since the acidity of the H-type acidic functional group of the allergen-reducing compound is easily maintained, and the allergen-reducing effect of the allergen reducing agent is improved. The pH of a 0.5% by mass aqueous solution of the allergen-reducing compound refers to the pH value at 25°C of an aqueous solution obtained by adding 0.5 g of the allergen-reducing compound to 99.5 g of purified water and mixing uniformly. When the concentration of the saturated aqueous solution of the allergen-reducing compound at 25°C is less than 0.5% by mass, the pH is the pH at 25°C of a suspension containing 0.5 parts by mass of the allergen-reducing compound and 99.5 parts by mass of water, in which the allergen-reducing compound has dissolved in water to its solubility and is saturated.

[0037] The molecular weight of the allergen-reducing compound is preferably 1000 or less, more preferably 800 or less, more preferably 600 or less, more preferably 500 or less, more preferably 450 or less, more preferably 400 or less, and more preferably 350 or less. When the molecular weight of the allergen-reducing compound is 1000 or less, the allergen-reducing effect of the allergen-reducing agent is improved.

[0038] The pKa1 of the allergen-reducing compound at 25° C. is preferably 4.5 or less, more preferably 4.2 or less, and even more preferably 4.0 or less. When the pKa1 of the allergen-reducing compound is 4.5 or less, the allergen-reducing effect of the allergen-reducing agent is improved.

[0039] When the allergen-reducing compound is a polyvalent acid, the allergen-reducing compound undergoes multiple ionization steps, and pKa1 refers to the pKa calculated based on the first ionization constant. + and A - When an acid dissociates into and reaches ionization equilibrium (1), the acid dissociation constant Ka is defined by equation (2), and pKa is defined as the common logarithm (3) of the reciprocal of the acid dissociation constant Ka.

[0040]

number

[0041] The pKa1 of an allergen-reducing compound is a value measured by titration. Specifically, the pKa1 can be determined by titrating the allergen-reducing compound with sodium hydroxide at 25°C and measuring the pH at 25°C at the half-equivalent point (the point at which half the amount required for complete neutralization is dropped).

[0042] The amount of H-type acidic functional groups in the allergen-reducing compound is preferably 4 mmol / g or more, more preferably 6.5 mmol / g or more, and more preferably 10 mmol / g or more. When the amount of H-type acidic functional groups in the allergen-reducing compound is 4 mmol / g or more, the allergen-reducing effect of the allergen-reducing agent is improved. The amount of H-type acidic functional groups in the allergen-reducing compound is preferably 18 mmol / g or less. When the amount of H-type acidic functional groups in the allergen-reducing compound is 18 mmol / g or less, the affinity of the allergen-reducing compound to allergens rather than water molecules is improved, and the allergen-reducing effect of the allergen-reducing agent is improved.

[0043] The amount of H-type acidic functional groups in the allergen-reducing compound is a value measured by titration. Specifically, about 1 g (Cg) of the dried allergen-reducing compound is precisely weighed, 200 mL of purified water is added to the allergen-reducing compound, and then titration is performed at 25°C using 0.1 mol / L aqueous sodium hydroxide solution to determine the amount of aqueous sodium hydroxide solution consumed up to the half-equivalent point (the point at which half the amount required for complete neutralization is dropped), and the amount of H-type acidic functional groups (mmol / g) in the allergen-reducing compound is calculated by the following formula. Amount of acidic functional groups in H-type (mmol / g) = 0.1 × C / D

[0044] The solubility of the allergen-reducing compound in water at 25° C. is preferably 10 g / L or less, more preferably 8 g / L or less, more preferably 7 g / L or less, and more preferably 6 g / L or less. When the solubility of the allergen-reducing compound in water at 25° C. is 10 g / L or less, the allergen-reducing compound has an improved affinity for allergens rather than water molecules, and the allergen-reducing effect of the allergen-reducing agent is improved.

[0045] The solubility of the allergen-reducing compound in water at 25°C refers to the mass (g) of the allergen-reducing compound in a saturated aqueous solution obtained by dissolving the allergen-reducing compound in 1 L of water. The solubility of the allergen-reducing compound in water at 25°C refers to a value measured at 25°C in accordance with OECD Chemicals Testing Guideline No. 105 (Water Solubility).

[0046] [Allergen reduction agent] The allergen-reducing agent contains an allergen-reducing compound as an active ingredient. The method for producing the allergen-reducing agent is not particularly limited, and the allergen-reducing agent can be produced by mixing the allergen-reducing compound with general-purpose additives as necessary in a general manner.

[0047] The allergen reducing agent is preferably in a particulate form. When the allergen reducing agent is in a particulate form, the allergen reducing agent can be more uniformly dispersed in the substrate, and the allergen reducing agent can be more uniformly present on the substrate surface. Thus, the allergen reducing effect can be more uniformly imparted to the substrate.

[0048] When the allergen reducing agent is particulate, the D90 particle size of the allergen reducing agent is preferably 2 μm or more, more preferably 3 μm or more, and more preferably 4 μm or more. The D90 particle size of the allergen reducing agent is preferably 25 μm or less, more preferably 22 μm or less, and more preferably 21 μm or less. When the D90 particle size is 2 μm or more, when the allergen reducing agent is contained in a substrate and used, the allergen reducing agent is easily exposed to the substrate surface, and the allergen reducing effect is improved. When the D90 particle size is 25 μm or less, when the allergen reducing agent is contained in a substrate and used, the processability is improved and the surface area is increased to facilitate contact with allergens, and the allergen reducing effect of the allergen reducing agent can be improved. Furthermore, the allergen reducing agent can be more uniformly attached to the substrate surface, and the allergen reducing effect can be imparted to the substrate in a more uniform state.

[0049] By adjusting the D90 particle size of the allergen reducing agent to preferably 2 to 25 μm, the inclusion of coarse particles in the allergen reducing agent is reduced. The allergen reducing compound has an H-type acidic functional group in the molecule, and by adjusting the D90 particle size of the allergen reducing agent to the above range, the processability when the allergen reducing agent is contained in a substrate and used is improved, and an excellent allergen reducing effect can be imparted to the substrate.

[0050] When the allergen reducing agent is particulate, the D50 particle size of the allergen reducing agent is preferably 0.5 μm or more, more preferably 1 μm or more, more preferably 1.5 μm or more, and more preferably 2.0 μm or more. The D50 particle size of the allergen reducing agent is preferably 14 μm or less, more preferably 12 μm or less, and more preferably 11 μm or less.

[0051] By setting the D50 particle size within the above-mentioned range (preferably 0.5 to 14 μm) and the D90 particle size to 2 to 25 μm in the allergen reduction agent, the inclusion of coarse particles having particle sizes significantly different from the D50 particle size in the allergen reduction agent can be reduced, and the particle size of the allergen reduction agent can be made more appropriate.

[0052] Furthermore, by adjusting the particle size of the allergen reduction agent to a more appropriate range, the amount of H-type acidic functional groups present on the surface of the particulate allergen reduction agent can be more appropriately adjusted, more effectively imparting excellent allergen reduction effects to the allergen reduction agent.

[0053] The D90 and D50 particle sizes of an allergen reduction agent refer to the particle sizes (90% cumulative particle size and 50% cumulative particle size) at which the cumulative frequency (cumulative from particles with smaller particle sizes) in the volume-based particle size distribution measured by laser scattering method is 90% and 50%, respectively.

[0054] Next, the usage of the allergen reducing agent will be described. The allergen reducing agent exerts an allergen reducing effect against various allergens by the action of the allergen reducing compound.

[0055] Allergens targeted by allergen reduction agents include animal allergens such as dust mite allergens (Der1, Der2) and allergens caused by dogs and cats (Can f1, Fel d1), airborne cedar pollen allergens (Cryj1, Cryj2), and plant allergens such as pollen. Particularly effective animal allergens include allergens from mites (mites, organisms of the Arthropoda Arachnida order, divided into seven main suborders: dorsal stigmata represented by Long-legged mites, tetrastigmata represented by Hard mites, posterior stigmata represented by Ixodes yamatans and Oriental spp., middle stigmata represented by house mites and sparrow mites, anterior stigmata represented by Lucanidae and Tarsus punctatus, house dust mites such as Dermatophagoides farinae, astigmatism represented by Tyrophagus putrescentiae, and cryptostigmata represented by Ophiopogon and Acanthurus nigricans). However, it is particularly effective against house dust mites, which are abundant in indoor dust, especially in bedding and cause allergic diseases.

[0056] The allergen reducing agent is used, for example, by being contained in a substrate to which an allergen reducing effect is to be imparted, to constitute an allergen reducing product. The substrate containing the allergen reducing agent exerts an allergen reducing effect as an allergen reducing product. The form in which the allergen reducing agent is contained in the substrate is not particularly limited, and examples thereof include a form in which the allergen reducing agent is mixed in the substrate, a form in which the allergen reducing agent is attached to the substrate surface, and a form in which the allergen reducing agent is kneaded into the substrate.

[0057] The allergen-reducing agent can be attached to the surface of a substrate by dissolving or dispersing the allergen-reducing agent in a solvent to prepare an allergen-reducing solution, and then applying the allergen-reducing solution to the substrate. The allergen-reducing solution may contain additives such as water-soluble substances, oils, emulsions, and suspensions, as necessary.

[0058] Examples of the solvent include water (preferably ion-exchanged water), alcohols (methyl alcohol, ethyl alcohol, propyl alcohol, etc.), hydrocarbons (toluene, xylene, methylnaphthalene, kerosene, cyclohexane, etc.), ethers (diethyl ether, tetrahydrofuran, dioxane, etc.), ketones (acetone, methyl ethyl ketone, etc.), and amides (N,N-dimethylformamide, etc.).

[0059] The content of the allergen reducing agent in 100% by mass of the allergen reducing solution is preferably 0.01% by mass or more, more preferably 0.1% by mass or more, and more preferably 1% by mass or more. The content of the allergen reducing agent in 100% by mass of the allergen reducing solution is preferably 20% by mass or less, more preferably 15% by mass or less, and more preferably 10% by mass or less.

[0060] The substrate into which the allergen reducing agent is to be incorporated is not particularly limited as long as it is capable of incorporating the allergen reducing agent, and examples include synthetic resin molded bodies, paints, wallpaper, decorative sheets, flooring materials, fibers, textile products (woven fabrics, nonwoven fabrics, knitted fabrics), interior goods and materials for vehicles (e.g., cars, airplanes, ships, etc.) (seats, child seats, and the foams that constitute these), kitchenware, baby products, architectural interior materials, etc.

[0061] The synthetic resin constituting the synthetic resin molded body is not particularly limited, and examples thereof include thermoplastic resins (e.g., polyethylene, polypropylene, polyvinyl chloride, polystyrene, polyvinyl acetate, polyurethane, Teflon (registered trademark), acrylonitrile butadiene styrene resin, acrylonitrile styrene resin, acrylic resin, polyvinyl alcohol, polyamide, polyacetal, polycarbonate, modified polyphenylene ether, polyester, polyethylene terephthalate, polybutylene terephthalate, cyclic polyolefin, polyphenylene sulfide, polytetrafluoroethylene, polysulfone, polyether sulfone, polyarylate, polyether ether ketone, thermoplastic polyimide, polyamide imide, etc.), thermosetting resins (e.g., phenolic resins, epoxy resins, melamine resins, urea resins, unsaturated polyester resins, alkyd resins, silicone resins, polyurethanes, thermosetting polyimides, etc.). The synthetic resins may be used alone or in combination of two or more.

[0062] The allergen reducing agent may be kneaded into a synthetic resin. As a method for kneading the allergen reducing agent into a synthetic resin, the allergen reducing agent is mixed into a raw synthetic resin to prepare a resin composition, and the resin composition is used to obtain an allergen reducing product of a desired shape as a molded product by a general-purpose synthetic resin molding method. Examples of the general-purpose synthetic resin molding method include extrusion molding, injection molding, and blow molding. The synthetic resin and the allergen reducing agent may be mixed to prepare a synthetic resin molding master batch, which is then mixed into the raw synthetic resin to produce an allergen reducing product as a molded product by a general-purpose synthetic resin molding method.

[0063] The content of the allergen reducing agent in 100% by mass of the resin composition is preferably 1% by mass or more, more preferably 3% by mass or more, and more preferably 5% by mass or more. The content of the allergen reducing agent in 100% by mass of the resin composition is preferably 20% by mass or less, more preferably 15% by mass or less, and more preferably 10% by mass or less.

[0064] The content of the allergen reducing agent in 100% by mass of the synthetic resin molding masterbatch is preferably 20% by mass or more, more preferably 30% by mass or more, and more preferably 50% by mass or more. The content of the allergen reducing agent in 100% by mass of the synthetic resin molding masterbatch is preferably 80% by mass or less, more preferably 70% by mass or less, and more preferably 60% by mass or less.

[0065] A method for physically fixing the allergen reducing agent to the fiber will be described. Examples of the method for physically fixing the allergen reducing agent to the fiber include (1) a method in which the allergen reducing agent is dissolved or dispersed in a solvent to prepare an allergen reducing solution, and the fiber is impregnated with the allergen reducing solution, (2) a method in which the allergen reducing solution is applied or sprayed onto the fiber surface, (3) a method in which the fiber is immersed in a binder in which the allergen reducing agent is dissolved or dispersed, and the allergen reducing agent is fixed to the fiber by the binder, and (4) a method in which the binder in which the allergen reducing agent is dissolved or dispersed is applied or sprayed onto the fiber surface, and the allergen reducing agent is fixed to the fiber by the binder. In the above methods (1) and (2), the allergen reducing solution may contain a binder. The solvent is the same as above, so the explanation is omitted.

[0066] The binder is not particularly limited as long as it can fix the allergen reducing agent to the fiber surface. For example, the binder may be a synthetic resin binder such as a one-liquid type urethane resin, a two-liquid type urethane resin, or the like, a silicone resin, an acrylic resin, a urethane acrylate resin, a polyester resin, an unsaturated polyester resin, an alkyd resin, a vinyl acetate resin, a vinyl chloride resin, an epoxy resin, or an epoxy acrylate resin, and the like, with the urethane resin being preferred.

[0067] As the paint, a conventionally known paint is used, for example, oil-based paint (e.g., mixed paint, oil varnish, etc.), cellulose paint, synthetic resin paint, etc. The paint also includes photocurable paint that is polymerized by irradiation with radiation such as ultraviolet light to generate a binder component.

[0068] The paint may contain additives such as pigments, plasticizers, curing agents, extenders, fillers, antioxidants, thickeners, and surfactants within the range that does not impair the physical properties of the paint. Examples of a method for preparing an allergen-reducing paint by incorporating an allergen-reducing agent in the paint include a method in which the allergen-reducing agent and the paint are supplied to a dispersing device and mixed uniformly. Examples of the dispersing device include a high-speed mill, a ball mill, and a sand mill.

[0069] The content of the allergen reducing agent in 100% by mass of the allergen reducing paint is preferably 0.01% by mass or more, more preferably 0.1% by mass or more, and more preferably 1% by mass or more. The content of the allergen reducing agent in 100% by mass of the allergen reducing paint is preferably 20% by mass or less, more preferably 15% by mass or less, and more preferably 10% by mass or less.

[0070] The architectural interior materials are not particularly limited, and examples thereof include flooring materials, wallpaper, ceiling materials, paints, doorknobs, switches, switch covers, and wax.

[0071] The vehicle interior goods and materials are not particularly limited, and examples thereof include seats, child seats, seat belts, car mats, seat covers, doors, ceiling materials, floor mats, door trims, instrument panels, consoles, glove boxes, hanging straps, and handrails.

[0072] When the allergen-reduced product is a textile product, the allergen reduction rate of the allergen-reduced product can be measured according to ISO 4333: Test for evaluation of reducing activity of proteins derived from pollen, dust mites, etc. When the allergen-reduced product is a molded body or laminate, the measurement of the allergen reduction rate (coating film) carried out in the examples described below can be used. In the measurement of the allergen reduction rate (coating film), the paint and substrate may be any that do not interfere with the measurement of the allergen reduction rate. EXAMPLES

[0073] The present invention will be described in more detail below using examples, but the present invention is not limited thereto.

[0074] The following compounds were prepared as allergen-reducing compounds that serve as active ingredients of the allergen-reducing agents.

[0075] [Allergen-reducing compounds] Phthalic acid [formula (1)] Methylenedisalicylic acid [formula (2)] cis-Δ4-Tetrahydrophthalic acid [formula (3)] Salicylic acid [formula (4)] 4-Aminobenzoic acid [Formula (5)] Benzilic acid [formula (6)] p-Toluenesulfonic acid [formula (7)] Phenylphosphonic acid [formula (12)]

[0076] [Other compounds] Adipic acid [formula (8)] Sebacic acid [formula (9)] Dodecanedioic acid [formula (10)] Sodium salicylate [formula (11)]

[0077] [ka]

[0078] [Chemical formula]

[0079] For the allergen-reducing compound, the molecular weight, pKa1 at 25°C, pH of a 0.5 mass% aqueous solution at 25°C, solubility in water at 25°C, and the amount of H-type acidic functional groups were measured in the above-described manner, and the results are shown in Table 1. In the table, "pKa1 at 25°C", "pH of a 0.5 mass% aqueous solution at 25°C", "solubility in water at 25°C", and "amount of H-type acidic functional groups" are denoted as "pKa1", "pH", "solubility", and "amount of acidic functional groups", respectively. In the table, "<X" (X is a numerical value) means "less than X".

[0080] (Examples 1 to 8 and Comparative Examples 1 to 4) An allergen-reducing agent containing the allergen-reducing compound shown in Table 1 as an active ingredient was prepared. The compounds of Comparative Examples 1 to 4 are described in the column of "allergen-reducing compound" for convenience.

[0081] The D50 particle size and D90 particle size of the obtained allergen-reducing agent were measured in the above-described manner, and the results are shown in Table 1.

[0082] Next, for the products processed using the allergen-reducing agents obtained in the examples and comparative examples, the allergen reduction rate, the effect on antibodies, and the antiviral activity value were measured in the following manner, and the results are shown in Table 1. In the table, "allergen reduction rate" and "effect on antibodies" are denoted as "reduction rate" and "antibody effect", respectively.

[0083] [Anti-allergen test] [Measurement of the allergen reduction rate of Japanese cedar pollen allergen (Cryj1)] An allergen-reducing paint was prepared by mixing 6 parts by mass of the allergen-reducing agent obtained in the Examples and Comparative Examples with 94 parts by mass of an ultraviolet-curing acrylic paint (manufactured by Coattec Co., Ltd., product name "AI-N2"). Next, a polyester film was prepared as a substrate. One side of this substrate was coated with the allergen-reducing paint to a thickness of 18 μm using a wire bar coater #8, and then ultraviolet rays with a wavelength of 365 nm were applied to the coating layer at 25° C. with an integrated light dose of 500 mJ / cm using a UV conveyor device (manufactured by iGraphics Co., Ltd., product name "ECS301G1"). 2 The ultraviolet-curable acrylic paint was cured by irradiating the paint so as to obtain an allergen-reduced substrate having a coating film of 18 μm in thickness on one side.

[0084] A freeze-dried powder of cedar pollen allergen (Cryj1) (ITEA Corporation, product name "Cedar Pollen Extract, code 10103") was dissolved in purified water to prepare an allergen solution containing 10μg / mL of cedar pollen allergen (Cryj1). PBS-T was then added to the allergen solution and mixed uniformly to prepare an allergen solution containing 15ng / mL of cedar pollen allergen (Cryj1).

[0085] The allergen-reduced substrate was cut into a flat square shape with sides measuring 5 cm, and 0.4 mL of the allergen solution was dropped onto the coating. The substrate was then covered with a flat square polyethylene film with sides measuring 4 cm and left at 25°C for 24 hours to prepare a test solution.

[0086] Next, the amount W1 (ng / mL) of cedar pollen allergen (Cryj1) present in the above test solution was measured by ELISA using cedar pollen allergen measurement kit A (ITEA, product name "Cedar Pollen Allergen (Cryj1) ELISA Kit, code 10204").

[0087] A blank substrate with a coating film formed on one side was prepared in the same manner as above, except that a blank paint containing only an ultraviolet-curable acrylic paint was used instead of the allergen-reduced paint. The amount of cedar pollen allergen present in the test solution, W0 (ng / mL), was measured in the same manner as above, except that a blank substrate was used instead of the allergen-reduced substrate. The allergen reduction rate (%) was calculated based on the following formula. It is shown in the "Reduction rate (%)" column in Table 1. Allergen reduction rate (%) = 100-(W1 / W0) x 100

[0088] [Measurement of the effect of cedar pollen allergen (Cryj1) on antibodies] An allergen-reduced substrate was prepared in the same manner as in the measurement of the reduction rate of cedar pollen allergen (Cryj1). 0.4 mL of PBS-T was dropped onto the coating film of the allergen-reduced substrate, which was then covered with a flat square polyethylene film with one side measuring 4 cm, and left at 25°C for 24 hours to prepare a test solution.

[0089] 100 μL of the test solution was dropped onto wells of an antibody-immobilized 96-well plate contained in the cedar pollen allergen measurement kit A (ITEA Corporation, product name "Cedar Pollen Allergen (Cryj1) ELISA Kit, code 10204") and allowed to stand for 1 hour at 25° C. Next, the wells were washed three times with PBS-T using a plate washer (Tecan Corporation, product name "HydroFlexPlus").

[0090] Next, ELISA was performed using the wells to measure the amount Z (ng / mL) of cedar pollen allergen (Cryj1) present in the allergen solution containing 15 ng / mL of cedar pollen allergen (Cryj1). The effect on antibodies (%) was calculated based on the following formula and is shown in the "Effect on antibodies (%)" column in Table 1. Effect on antibody (%) = 100-(Z / 15) x 100

[0091] [Measurement of the reduction rate of mite allergen (Derf1) and the effect on antibodies] The allergen reduction rate (%) and effect on antibodies (%) of mite allergen (Derf1) were calculated in the same manner as for the measurement of the cedar pollen allergen reduction rate (%) and effect on antibodies (%), except that freeze-dried powder of mite allergen (Derf1) (ITEA Corporation, product name "Mite (Df) Culture Medium Extract, code 10102") was used instead of freeze-dried powder of cedar pollen allergen (Cryj1), and mite allergen measurement kit A (ITEA Corporation, product name "Mite Allergen (Derf1) ELISA Kit, code 10205") was used instead of cedar pollen allergen measurement kit A (ITEA Corporation, product name "Cedar Pollen Allergen (Cryj1) ELISA Kit, code 10204"), and are shown in the "Reduction Rate (%)" and "Antibody Effect (%)" columns in Table 1, respectively.

[0092] (Antiviral activity value) A flat square nonwoven fabric with sides of 10 cm (trade name "Kimwipe S-200" manufactured by Nippon Paper Crecia Co., Ltd.) was prepared. The surface of the coating film of the allergen-reduced substrate was wiped with the nonwoven fabric by reciprocating 10 times to obtain a test coating film.

[0093] The obtained test coating film was subjected to antiviral tests against influenza virus and feline calicivirus in accordance with ISO 21702. After the reaction, the virus suspension was subjected to the plaque method to measure the virus infectivity (common logarithm) (PFU / cm 2 ) was calculated.

[0094] For the coating of the blank substrate, the virus infectivity (common logarithm value) (PFU / cm 2 The virus infectivity value (common logarithm) of the coating film on the blank substrate was 6.5 PFU / cm 2 It was.

[0095] The antiviral activity value was calculated by subtracting the virus infectivity value of the test coating film from the virus infectivity value of the coating film of the blank substrate, and the results are shown in the "Anti-influenza activity value" and "Anti-feline calicivirus activity value" columns of Table 1, respectively.

[0096]

Table 1

Claims

1. An allergen-reducing agent comprising as an active ingredient an allergen-reducing compound having at least one H-type acidic functional group selected from the group consisting of a carboxy group, a sulfo group and a phosphonic acid group, and in which the H-type acidic functional group is bonded to a cyclic skeleton via 0 to 2 carbon atoms.

2. 2. The allergen-reducing agent according to claim 1, wherein the cyclic skeleton of the allergen-reducing compound is an aromatic ring skeleton or an alicyclic skeleton.

3. 3. The allergen reducing agent according to claim 1, wherein the H-type acidic functional group is a carboxy group or a sulfo group.

4. 3. The allergen-reducing agent according to claim 1, wherein the molecular weight of the allergen-reducing compound is 1,000 or less.

5. 3. The allergen-reducing agent according to claim 1, wherein the allergen-reducing compound has a pKa1 at 25° C. of 4.5 or less.

6. 3. The allergen-reducing agent according to claim 1, wherein the amount of H-type acidic functional groups in the allergen-reducing compound is 4 mmol / g or more.

7. 3. The allergen-reducing agent according to claim 1, wherein the solubility of the allergen-reducing compound in water at 25° C. is 10 g / L or less.

8. 3. The allergen-reducing agent according to claim 1, wherein a 0.5% by mass aqueous solution of the allergen-reducing compound has a pH of 4.2 or less at 25°C.

9. The allergen reducing agent according to claim 1 or 2, characterized in that the D90 particle size is 2 to 25 μm.

10. 3. The allergen reducing agent according to claim 1, wherein the D50 particle size is 0.5 to 14 μm.

11. An allergen-reducing paint comprising the allergen-reducing agent according to claim 1 or 2 and a paint.

12. A masterbatch for synthetic resin molding, comprising the allergen reducing agent according to claim 1 or 2 and a synthetic resin.

Images